Robert E. Desjardins
Gründer bei Drais Pharmaceuticals Inc.
Profil
Robert E.
Desjardins is the founder of AkaRx, Inc. (founded in 2005) and Drais Pharmaceuticals Inc. (founded in 2007).
At AkaRx, Inc., he held the title of President & Chief Executive Officer from 2005 to 2010.
At Drais Pharmaceuticals Inc., he currently holds the title of Director.
In addition to his founding positions, Dr. Desjardins has held former jobs at Georgetown University as an Adjunct Professor, The Burroughs Wellcome Fund as Head-Anti-Infective Clinical Research, and Lederle Pharmaceuticals as a Principal.
Dr. Desjardins obtained a doctorate degree from Loyola University of Chicago.
Aktive Positionen von Robert E. Desjardins
| Unternehmen | Position | Beginn |
|---|---|---|
Drais Pharmaceuticals Inc.
 Drais Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ. | Gründer | 01.01.2007 |
Ehemalige bekannte Positionen von Robert E. Desjardins
| Unternehmen | Position | Ende |
|---|---|---|
| Lederle Pharmaceuticals | Corporate Officer/Principal | - |
The Burroughs Wellcome Fund
 The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Technik-/Wissenschafts-/F&E-Leiter | 06.05.2011 |
| Georgetown University | Corporate Officer/Principal | - |
AkaRx, Inc.
 AkaRx, Inc. Pharmaceuticals: MajorHealth Technology AkaRx, Inc. engages in the develop and manufacture of biopharmaceutical products for applications in hematology and therapeutic treatments for clinical-stage cancer. It offers thrombocytopenia treatment avatrombopag. The company was founded by Robert E. Desjardins and Donna Tempel in 2005 and is headquartered in NJ. | Gründer | - |
Ausbildung von Robert E. Desjardins
| Loyola University of Chicago | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
AkaRx, Inc.
AkaRx, Inc. Pharmaceuticals: MajorHealth Technology AkaRx, Inc. engages in the develop and manufacture of biopharmaceutical products for applications in hematology and therapeutic treatments for clinical-stage cancer. It offers thrombocytopenia treatment avatrombopag. The company was founded by Robert E. Desjardins and Donna Tempel in 2005 and is headquartered in NJ. | Health Technology |
Drais Pharmaceuticals Inc.
Drais Pharmaceuticals Inc. Pharmaceuticals: MajorHealth Technology Drais Pharmaceuticals, Inc. manufactures pharmaceutical and provides therapeutic treatments. The company was founded by Donna L. Tempel and Robert E. Desjardins in 2007 and is headquartered in Bridgewater, NJ. | Health Technology |
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Miscellaneous |
| Lederle Pharmaceuticals |
